蒽环类药物联用右雷佐生治疗乳腺癌的药物经济学评价

发布时间：2018-05-11 12:39

本文选题：蒽环类药物 + 右雷佐生　；参考：《中国卫生经济》2017年07期

【摘要】：目的:对蒽环类药物联用右雷佐生(又称右丙亚胺)治疗乳腺癌进行药物经济学评价。方法:从支付方角度出发,采用Markov模型,对于蒽环类药物联用右雷佐生(试验组)和不联用右雷佐生(对照组)两种乳腺癌治疗方案进行成本效用分析。成本参数来源于广东地区的医院抽样数据,疾病概率和效用参数来源于文献。结果:试验组和对照组的治疗效果指标为质量调整生命年,分别为12.86QALYs和12.35QALYs,相应的终身直接医疗费用分别为15.51万元和14.83万元。试验组的效果更好,同时费用更高,增量成本效果比(ICER)为13 155元/QALY,显著低于2015年中国的3倍人均GDP(148 053元)。敏感性分析显示了研究结果的稳健性。结论:从长期来看,对于乳腺癌患者,相对单用蒽环类药物,蒽环类药物联用右雷佐生治疗乳腺癌更具有成本效果优势。
[Abstract]:Objective: to evaluate the pharmacoeconomics of anthracycline combined with dextroxacin (dextromine) in the treatment of breast cancer. Methods: Markov model was used to analyze the cost and utility of anthracycline drugs combined with dextroxacin (trial group) and control group (control group). Cost parameters are derived from hospital sampling data in Guangdong, disease probability and utility parameters are derived from literature. Results: the quality adjusted life years (12.86QALYs and 12.35 QALYs) were the effective indexes of the treatment in the experimental group and the control group. The corresponding life-long direct medical expenses were 155100 yuan and 148300 yuan respectively. The effect of the test group was better and the cost was higher. The incremental cost effect was 13,155 yuan / QALY, which was significantly lower than that of China's per capita GDP(148 in 2015. Sensitivity analysis shows the robustness of the results. Conclusion: in the long run, anthracycline combined with dextroxacin is more cost effective than anthracycline alone in the treatment of breast cancer.
【作者单位】：中国药科大学国际医药商学院;北京大学中国卫生经济研究中心;北京大学国家发展研究院;
【分类号】：R956

【参考文献】